Xenpozyme®
XENPOZYME® (olipudase alfa-rpcp) is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
MANUFACTURER: Genzyme Corporation |
CLASS: Enzyme Replacement Therapy (ERT) |
WHAT IT TREATS: Acid Sphingomyelinase Deficiency (ASMD) also know as Niemann-Pick disease type A, A/B and B |
PRESCRIBED BY: Neurologists, Pulmonologists
|
HOW ADMINISTERED: Intravenous Infusion |
FREQUENCY: Every two weeks |
Length of infusion: 3-4 hrs |
